Elicio Therapeutics reports Q1 EPS (87c), consensus (83c)

“In the first quarter, we made continued progress toward our upcoming Phase 2 AMPLIFY-7P event-driven interim analysis, expected next quarter-a key milestone for Elicio and for patients facing pancreatic ductal adenocarcinoma,” said Robert Connelly, CEO of Elicio. “We believe ELI-002 represents a potentially transformative approach in the treatment of mKRAS-driven tumors, and the upcoming randomized interim data readout in PDAC will be a critical validating opportunity for our AMP platform. To this end, we believe the upcoming results could demonstrate ELI-002’s impact not only in PDAC-a particularly difficult-to-treat cancer with a 5-year survival rate of 13%-but also provide momentum for broader application of our technology across additional indications. Importantly, our current cash runway extends into the fourth quarter of 2025, beyond the anticipated AMPLIFY-7P Phase 2 interim analysis.”